Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT00706030

Public ClinicalTrials.gov record NCT00706030. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Study identification

NCT ID
NCT00706030
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Puma Biotechnology, Inc.
Industry
Enrollment
92 participants

Conditions and interventions

Interventions

  • neratinib Drug
  • vinorelbine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 28, 2008
Primary completion
Sep 30, 2009
Completion
Jun 6, 2018
Last update posted
Aug 8, 2018

2008 – 2018

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
Highlands Oncology Group Fayetteville Arkansas 72703
City of Hope National Medical Center Duarte California 91010
Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center Lebanon New Hampshire 03756
Columbia University Medical Center New York New York 10032
Hematology Oncology Associates of Rockland Nyack New York 10960
Albert Einstein Cancer Center The Bronx New York 10461
Carolinas Hematology-Oncology Associates Charlotte North Carolina 28203
Fox Chase Cancer Center Philadelphia Pennsylvania 19111

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00706030, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 8, 2018 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00706030 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →